Table 3.

Top 10 original articles concerning the research of PCa immunotherapy.

Title	Journals	First author	Year	Citations
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer	New England Journal of Medicine	Topalian, Suzanne L.	2012	8,193
Sipuleucel-T immunotherapy for castration-resistant prostate cancer	New England Journal of Medicine	Kantoff, Philip W.	2010	3,629
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates	Journal of Clinical Oncology	Brahmer, Julie R.	2010	2,033
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy	Oncogene	Fulda, S.	2006	1,556
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential	Cell	Sharma, Padmanee	2015	1,305
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial	Lancet Oncology	Kwon, Eugene D.	2014	941
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer	Journal of Clinical Oncology	Small, Eric J.	2006	831
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer	Clinical Cancer Research	Kershaw, Michael H.	2006	807
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients	Proceedings of the National Academy of Sciences of the United States of America	Hodi, F.S.	2003	743
CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy	Annual Review of Immunology	Chambers, C.A.	2001	724